AnaBios Corporation

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
    • Generic Drugs
  • Contract Research Organization-CRO
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
  • Services
See more in Biomedtracker

Latest on AnaBios Corporation

Scrip

Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal

 
• By Joseph Haas, Jo Shorthouse, Ian Haydock, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Purdue Partners With Alivio

Scrip

Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Scrip

Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding

 
• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner

AnaBios Brings In $10m Series B Round, Including $4.2m From Principia AnaBios Corp. (focused on pain and cardiovascular and neurodegenerative diseases) closed a $10m Series B round, which included

Scrip

Pain Licensing: Upfront Gains Fall As Deals Get More Experimental

 
• By Lucie Ellis-Taitt

Surprisingly, companies developing pain therapeutics – a well-served market – are also some of the most prolific researchers, with more than 341 Phase I to Phase III/IV active clinical trials as of No